Sanofi, Japanese firm team up for monoclonal antibody

05/14/2009 | Reuters

Sanofi-Aventis agreed to co-develop Kyowa Hakko Kirin's anti-LIGHT fully human monoclonal antibody as a treatment for inflammation. The licensing deal, worth as much as $315 million, grants Sanofi worldwide rights to the drug, although the companies will jointly work on the product in Japan and Asia.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA